|Bid||6.48 x 3200|
|Ask||6.50 x 3000|
|Day's range||6.20 - 6.58|
|52-week range||4.00 - 17.86|
|Beta (5Y monthly)||2.04|
|PE ratio (TTM)||2.41|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
As of late, it has definitely been a great time to be an investor in Cronos Group.
The webcasts will be available on the Investors section of the Company’s website at ir.thecronosgroup.com/events-presentations. Cronos Group is an innovative global cannabinoid company with international production and distribution across five continents. Cronos Group is committed to building disruptive intellectual property by advancing cannabis research, technology and product development.
Aurora Cannabis (NYSE: ACB) stock has skyrocketed by a triple-digit percentage in recent days after the Canadian cannabis producer reported better-than-expected fiscal 2020 third-quarter results. You might think that after this huge gain, Aurora is outperforming rival Cronos Group (NASDAQ: CRON), which posted Q1 results earlier this month that were below expectations. Which of these two marijuana stocks is the better pick going forward?
The stock of Cronos Group (NASDAQ: CRON) ended the week on a high note, rising more than 8% on Friday to outpace the gains of the broader market. Cronos has a major CBD asset in its Lord Jones product line. Although the results of the study, conducted by researchers at the University of Lethbridge in Canada, were published last month, they are only now hitting the news media and getting on the radar of investors.
Cannabis investors sometimes have to take earnings results with a grain of salt. Relying just on sales and net income figures can lead to incorrect conclusions. Cronos has recorded a positive net income figure in each of its past five quarterly results.
Shares of several top Canadian cannabis producers soared today after one of their peers, Aurora Cannabis (NYSE: ACB), reported better-than-expected fiscal 2020 third-quarter revenue growth after the market closed on Thursday. Canopy Growth (NYSE: CGC) stock was up 13.4% as of 3:38 p.m. EDT on Friday, while shares of Cronos Group (NASDAQ: CRON) and OrganiGram Holdings (NASDAQ: OGI) were up 10.3% and 13.5%, respectively. Investors now appear to be increasingly optimistic that the rest of the Canadian cannabis industry could also enjoy a turn for the better after a challenging period following Aurora's surprisingly positive results.
Due to the continued public health concerns related to the COVID-19 pandemic, to mitigate risks to the health and safety of our communities, shareholders, employees and other stakeholders, Cronos Group will be conducting the meeting in a virtual-only format via live audio webcast. Registered shareholders and duly appointed proxyholders will have an equal opportunity to participate in the 2020 Annual and Special Meeting online regardless of their geographic location, including a chance to ask questions and vote. The Company’s proxy statement describing the formal business to be conducted at the meeting and containing detailed instructions about how to participate in the meeting is available on the Investors section of the Company’s website at https://ir.thecronosgroup.com/investor-relations.
For years, the marijuana industry was the hottest investment on Wall Street. Over the past 13-plus months, cannabis stocks have been raked over the coals. Regulatory-based supply issues in Canada, high tax rates on legal-channel pot products in key U.S. states, and the inability of many North American pot stocks to access traditional forms of financing have quickly pulled the rug out from beneath this blazing hot industry.
Over the last 20 months, they have been impacted by valuation issues, a thriving black market, lower than expected demand, high inventory levels, mounting losses, health issues from the vaping scandals, and much more. The investor euphoria that surrounded cannabis stocks when Canada legalized marijuana for recreational use seems like a distant dream. The marijuana sector is still at a nascent stage and is expected to grow at a rapid pace in the upcoming decade.
LOS ANGELES, May 10, 2020 -- The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of the following publicly traded companies..
SAN FRANCISCO, May 09, 2020 -- Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact.
Thank you, Natalia and thank you for joining us today to review Cronos Group's first quarter 2020 financial and business performance. Today, I'm joined by our Chairman, President and CEO, Mike Gorenstein; our CFO, Jerry Barbato and our EVP of Legal and Regulatory Affairs, Xiuming Shum. Cronos Group issued a news release announcing our financial results this morning, which are filed on our EDGAR and SEDAR profiles.
NEW YORK, May 08, 2020 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cronos Group, Inc. (NASDAQ: CRON) between May 9, 2019 and.
The Law Offices of Frank R. Cruz reminds investors of the upcoming May 11, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Cronos Group Inc. ("Cronos" or the "Company") (NASDAQ: CRON) securities between May 9, 2019, and March 2, 2020, inclusive (the "Class Period").
Cronos (CRON) delivered earnings and revenue surprises of 385.71% and -21.68%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Fermented target cannabinoid, CBGA, using cannabinoid strains at Cronos Fermentation R&D labs Successfully completed first dried flower shipment to Israel, as Cronos Israel.
Over the past 13 months, the marijuana industry has done a 180 -- and not the good kind. Following a first quarter in 2019 that saw more than a dozen pot stocks gain at least 70%, the past 13 months have featured across-the-board declines for North American cannabis stocks of 50% to 95%. Meanwhile, in the U.S., high tax rates on legal cannabis have made it virtually impossible for retailers to compete with the black market.
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to email@example.com.
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Cronos Group Inc. ("Cronos" or "the Company") (NASDAQ: CRON) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Cronos securities between May 9, 2019, and March 2, 2020, both dates inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Cronos had engaged in significant transactions for which its revenue recognition was inappropriate; (2) the foregoing would foreseeably necessitate reviews that would delay the Company’s ability to timely file its periodic reports; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that purchased or acquired the securities of Cronos Group, Inc. ("Cronos" or the "Company") (NASDAQ: CRON) between May 9, 2019, and March 2, 2020 (the "Class Period"). The lawsuit filed in the United States District Court for the Eastern District of New York alleges violations of the Securities Exchange Act of 1934.